Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SBTX · Entity 883 | Director | June 10, 2022 | June 13, 2022 |
| Janux Therapeutics, Inc.JANX · Entity 4864 | Director | June 11, 2026 | June 13, 2026 |
| OTONOMY, INC.OTIC · Entity 116495 | Director | November 28, 2022 | November 29, 2022 |
| Orthofix Medical Inc.OFIX · Entity 1975 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 10, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-06-09 | Direct | 18,000 |
Reported balance
After 2022-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 18,000 · Balance 18,000 F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Janux Therapeutics, Inc.
Report date June 11, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,598 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,500 · Balance 79,598 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.66 · Expires 2036-06-10 | Direct | 15,500 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 15,500 · Balance 15,500 F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
OTONOMY, INC.
Report date November 28, 2022 · Filed November 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,400 |
Reported balance
After 2022-11-28 transaction · row 1
1 source rowRow 1 · 2022-11-28 · Sale · Disposed 42,242 · Balance 3,400 F1: This sale price represents the weighted average sale price of the shares sold ranging from $0.1014 to $0.1031 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,600 |
Reported balance
Holding disclosure · report date 2022-11-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,600 |
Filing footnotes · ownership attribution and instrument terms
F1: This sale price represents the weighted average sale price of the shares sold ranging from $0.1014 to $0.1031 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Orthofix Medical Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,300 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 14,965 · Balance 43,300 F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2: Includes 21,934 previously reported deferred stock units and 750 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
F2: Includes 21,934 previously reported deferred stock units and 750 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b).
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMEDISYS INC
Report date August 14, 2025 · Filed August 14, 2025
Section 16 reporting ended · disclosed 2025-08-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-14 transaction · row 1
1 source rowRow 1 · 2025-08-14 · Disposition to issuer · Disposed 9,818 · Balance 0 F1: On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax. F2: Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.
F2: Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time.
CONNECTURE INC
Report date April 25, 2018 · Filed April 27, 2018
Section 16 reporting ended · disclosed 2018-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-25 transaction · row 1
1 source rowRow 1 · 2018-04-25 · Disposition to issuer · Disposed 136,898 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 4, 2018, among Connecture, Inc., FP Healthcare Holdings, Inc. and FP Healthcare Merger Sub Corporation, the shares were cancelled and converted into the right to receive $0.35 in cash, without interest, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 4, 2018, among Connecture, Inc., FP Healthcare Holdings, Inc. and FP Healthcare Merger Sub Corporation, the shares were cancelled and converted into the right to receive $0.35 in cash, without interest, less any applicable withholding taxes.
NUVASIVE INC
Report date September 01, 2023 · Filed September 05, 2023
Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 1
1 source rowRow 1 · 2023-09-01 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-01 · Disposition to issuer · Disposed 4,001 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-01 · Disposition to issuer · Disposed 2,822 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-01 · Disposition to issuer · Disposed 2,130 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-01 · Disposition to issuer · Disposed 3,230 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-01 · Disposition to issuer · Disposed 2,577 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-01 · Disposition to issuer · Disposed 3,095 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-09-01 · Disposition to issuer · Disposed 2,702 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-01 · Disposition to issuer · Disposed 2,501 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Synthorx, Inc.
Report date January 23, 2020 · Filed January 24, 2020
Section 16 reporting ended · disclosed 2020-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2028-05-16 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-23 · Disposition to issuer · Disposed 62,412 · Balance 0 F1: This option, which provided for the shares to be immediately exercisable, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $4,185,972.84, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.40 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-23 · Disposition to issuer · Disposed 15,335 · Balance 0 F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $852,626, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which provided for the shares to be immediately exercisable, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $4,185,972.84, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $852,626, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2020 Filed Jan 24, 2020 18:20 UTC | Synthorx, Inc. THOR · Entity 152202 | Disposition to issuerStock Option (right to buy) · Derivative | 62,412 | $67.07 Strike: $0.93 | $4,185,972.84 |
DisclosureSEC source: 0001209191-20-004920 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,412 shares Expires 2028-05-16 F1 · derivative.exercise_date: This option, which provided for the shares to be immediately exercisable, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $4,185,972.84, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:00 UTC | AMEDISYS INC AMED · Entity 16075 | GrantCommon Stock | 780 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028189 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780 F1 · shares: The shares reported are subject to time-based vesting conditions and will vest 100% on June 7, 2020, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 17:01 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-19-036834 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2029-06-10 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 18:43 UTC | Synthorx, Inc. THOR · Entity 152202 | GrantStock Option (right to buy) · Derivative | 15,335 | $0.00 Strike: $12.40 | $0.00 |
DisclosureSEC source: 0001209191-19-035972 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,335 Underlying: Common Stock · 15,335 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 12 months following June 7, 2019, provided that the option will be fully vested on the date of the Issuer's next annual stockholder meeting. Read SEC document |
| May 09, 2019 Filed May 10, 2019 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 2,577 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029059 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,577 Underlying: Common Stock · 2,577 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 19:36 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001209191-18-038874 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-06-18 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 18:01 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 3,230 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028410 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,230 Underlying: Common Stock · 3,230 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2019 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2019 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 17:45 UTC | CONNECTURE INC CNXR · Entity 167208 | Disposition to issuerCommon Stock | 136,898 | $0.35 | $47,914.30 |
DisclosureSEC source: 0001209191-18-026690 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of January 4, 2018, among Connecture, Inc., FP Healthcare Holdings, Inc. and FP Healthcare Merger Sub Corporation, the shares were cancelled and converted into the right to receive $0.35 in cash, without interest, less any applicable withholding taxes. Read SEC document |
| June 20, 2017 Filed Jul 14, 2017 18:29 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.05 | $0.00 |
DisclosureSEC source: 0001209191-17-045248 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-20 F1 · derivative.exercise_date: The shares subject to the option vest in full on the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 25, 2017 Filed May 25, 2017 18:21 UTC | CONNECTURE INC CNXR · Entity 167208 | GrantCommon Stock | 80,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-035552 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,898 Read SEC document |
| May 18, 2017 Filed May 22, 2017 17:45 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 2,130 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034399 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,130 Underlying: Common Stock · 2,130 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2018 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2018 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 17:05 UTC | CONNECTURE INC CNXR · Entity 167208 | GrantCommon Stock | 27,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-153086 · doc4.xml · nonDerivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,410 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.